"Chevy Chase Clinical Research is the largest research center of its kind in the region with approximately 90,000 patients in its database. Established in 1996 as part of Affiliated Research Centers, it is now an independent research site. Under the direction of Medical Director Dr. Aamir Ali, more than 300 studies have been conducted in all areas of Gastroenterology and some areas of Internal Medicine."

During the past decade, MGG Group Co., Inc., Chevy Chase Clinical Research conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 9 clinical trials were completed, i.e. on average, 69.2% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 7 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MGG Group Co., Inc., Chevy Chase Clinical Research" #1 sponsor was "Pfizer" with 7 trials, followed by "Galapagos NV" with 3 trials sponsored, "Allergan" with 1 trials sponsored, "Bausch Health Americas, Inc." with 1 trials sponsored and "Boehringer Ingelheim" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MGG Group Co., Inc., Chevy Chase Clinical Research" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator and "Galapagos NV" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "MGG Group Co., Inc., Chevy Chase Clinical Research" are "Ulcerative Colitis" (8 trials), "Crohn's Disease" (3 trials), "Chronic Idiopathic Constipation" (1 trials), "Colorectal Cancer" (1 trials) and "Colorectal Neoplasms" (1 trials). Many other conditions were trialed in "MGG Group Co., Inc., Chevy Chase Clinical Research" in a lesser frequency.

Most popular intervention types in "MGG Group Co., Inc., Chevy Chase Clinical Research" are "Drug" (15 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Filgotinib" (4 trials), "PF-06651600" (2 trials), "PF-06700841" (2 trials) and "APT-1011" (1 trials). Other intervention names were less common.

The vast majority of trials in "MGG Group Co., Inc., Chevy Chase Clinical Research" are 17 trials for "All" genders.

Currently, there are NaN active trials in "MGG Group Co., Inc., Chevy Chase Clinical Research". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 11 completed trials in MGG Group Co., Inc., Chevy Chase Clinical Research, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in MGG Group Co., Inc., Chevy Chase Clinical Research, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".